ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Neuroprotective effects of Interleukin-1 receptor antagonism after cardiac arrest: an experimental rat study.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the histopathological and biochemical neuroprotective effects of IL-1 receptor antagonist (anakinra) administration in an asphyxia-induced cardiac arrest model. A total of 24 Wistar albino rats were randomized into three groups: control, sham (cardiac arrest + saline), and anakinra (cardiac arrest + 50 mg/kg anakinra). Brain tissues were evaluated using a six-parameter semi-quantitative histopathological scoring system, and the composite damage score (CDS) was calculated (0-12). Levels of antioxidant and oxidative markers SOD, CAT, GSH, and MDA were analyzed spectrophotometrically. In the anakinra-treated group, neuronal degeneration, gliosis, and neuropil edema levels were significantly lower compared to the sham group (p < 0.01 for all). Although vascular congestion and perivascular edema were observed to be lower in the anakinra group, this reduction was not statistically significant in score analyses compared to the sham group (p > 0.05). No significant difference was found between the groups in terms of PMNL infiltration. In biochemical analyses, SOD, CAT, and GSH levels were found to be significantly higher in the anakinra group compared to both the sham and control groups (p < 0.001), while MDA levels were significantly lower (p < 0.001). These findings indicate that anakinra reduces oxidative stress and significantly alleviates neurohistopathological damage in the experimental model. Anakinra administration significantly reduced short-term hypoxic-ischemic brain damage following cardiac arrest, both in terms of histopathological and oxidative stress parameters. The findings suggest that targeting the IL-1-mediated inflammatory response could be an important neuroprotective approach; however, further studies are needed regarding dose, timing of administration, and long-term neurological function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.